DCM
KYMR icon

Driehaus Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Driehaus Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Sell
919,233
-124,350
-12% -$10.7M 0.61% 45
2026
Q1 		$86.9M Sell
1,043,583
-25,655
-2% -$2.03M 0.64% 39
2025
Q4 		$83.2M Buy
1,069,238
+130,144
+14% +$8.79M 0.57% 49
2025
Q3 		$53.2M Buy
939,094
+5,204
+0.6% +$235K 0.38% 84
2025
Q2 		$40.8M Sell
933,890
-234,901
-20% -$8.09M 0.33% 103
2025
Q1 		$32M Sell
1,168,791
-221,581
-16% -$8.08M 0.31% 105
2024
Q4 		$55.9M Buy
1,390,372
+61,669
+5% +$2.79M 0.46% 74
2024
Q3 		$62.9M Buy
1,328,703
+1,105,290
+495% +$48.8M 0.54% 53
2024
Q2 		$6.67M Buy
+223,413
New +$7.74M 0.06% 246
2022
Q2 		– Sell
-199,244
Closed -$8.43M – 403
2022
Q1 		$8.43M Sell
199,244
-440,238
-69% -$18.6M 0.1% 254
2021
Q4 		$40.6M Buy
639,482
+56,290
+10% +$3.28M 0.41% 75
2021
Q3 		$34.3M Buy
583,192
+551,611
+1,747% +$32M 0.41% 73
2021
Q2 		$1.53M Buy
+31,581
New +$1.37M 0.02% 324

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Driehaus Capital Management's KYMR Position: Q2 2026 in Review

Driehaus Capital Management reduced its Kymera Therapeutics (KYMR) stake by 12% in Q2 2026, selling an estimated $10.7M and leaving 919,233 shares worth $105M. The position accounts for 0.61% of the portfolio, ranked #45.

Driehaus Capital Management first reported a position in KYMR in Q2 2021 and has held it in 13 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Driehaus Capital Management held 919,233 shares of Kymera Therapeutics worth $105M as of Q2 2026.
  • Driehaus Capital Management sold 124,350 Kymera Therapeutics shares in Q2 2026, an estimated $10.7M.
  • Kymera Therapeutics made up 0.61% of Driehaus Capital Management's portfolio in Q2 2026, its #45 holding.
  • Driehaus Capital Management first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.